AGN-151586 + OnabotulinumtoxinA for Frown Lines
Trial Summary
The trial information does not specify whether you need to stop taking your current medications. Please consult with the trial coordinators for more details.
OnabotulinumtoxinA, used for treating facial lines, has been shown to be generally safe with a favorable benefit-risk profile, and is well tolerated by most patients. Some studies report minimal side effects, such as mild itching (pruritus), but these are rare.
12345The combination of AGN-151586 and OnabotulinumtoxinA for treating frown lines is unique because it potentially offers a novel approach by combining two agents, where OnabotulinumtoxinA is already known for its effectiveness in reducing frown lines, and AGN-151586 may enhance or complement this effect, although specific details about AGN-151586's role are not provided in the available research.
12367Eligibility Criteria
This trial is for adults with moderate to severe frown lines who want to try new treatments. Participants should be healthy overall and not have any conditions that might interfere with the study or pose a risk when receiving injections in the face.Inclusion Criteria
Exclusion Criteria